AzTrials
AzTrials

Lung TransplantNCT05898776

10°C vs 4°C Lung Preservation RCT

A study testing Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation in people with Lung Transplant and Organ Preservation, run by University Health Network, Toronto at 17 sites in 8 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25%… Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Lung Transplant, Organ Preservation
What is being tested?
Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
317 participants
Where
17 sitesin 8 countries
Study dates
9 Jun 2023to 22 Nov 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Donor Inclusion Criteria

  • Donation after brain death (DBD) or donation after cardiac death (DCD)
  • Donor lungs are suitable to go straight to LTx (i.e., do not need ex vivo lung perfusion (EVLP) assessment)

Donor Exclusion Criteria

  • Concerns with organ preservation technique
  • Need for EVLP assessment

Recipient Inclusion Criteria

  • 18-80 years old
  • Primary lung transplantation
  • Bilateral lung transplantation

Recipient Exclusion Criteria

  • Re-transplantation
  • Multi-organ transplantation
  • Single lung transplantation
  • Participation in a contraindicating trial

Trial locations and contacts

17 sites in 8 countries.

17 sites in 8 countries

United States7 sites
  • University of Miami

    Coral Gables, Florida, 33146

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390

  • Corewell Health Research Institute

    Grand Rapids, Michigan, 49503

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232

  • Dignity Health (St. Joseph's Hospital and Medical Center)

    Phoenix, Arizona, 85050

  • Mayo Clinic

    Rochester, Minnesota, 55905

  • University of California San Francisco

    San Francisco, California, 94143

Other trials in United States

Canada2 sites
  • Centre hospitalier de l'Université de Montréal

    Montreal, Quebec, H2X0A9

  • University Health Network (Toronto General Hospital)

    Toronto, Ontario, M5G 2C4

Other trials in Canada

Spain2 sites
  • Hospital Universitario 12 de Octubre

    Madrid, 28041

  • Hospital Universitario Puerta de Hierro-Majadahonda

    Madrid

Other trials in Spain

Switzerland2 sites
  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Lausanne

  • University Hospital Zurich

    Zurich

Other trials in Switzerland

Australia1 site
  • St Vincent's Hospital Sydney Limited

    Sydney, New South Wales, 2010

Other trials in Australia

Austria1 site
  • Medical University of Vienna

    Vienna

Other trials in Austria

Belgium1 site
  • University Hospitals Leuven

    Leuven

Other trials in Belgium

France1 site
  • The Saint Joseph Hospital Foundation (Hôpital Marie Lannelongue)

    Paris, 75014

Other trials in France

About this study

Official title: Safety of 10°C Lung Preservation vs. Standard of Care: A Multi-Centre Prospective Non-Inferiority Trial

Despite lung transplantation (LTx) being the most effective treatment for end-stage lung disease, its success rate is lower than that of other solid organ transplantations. Primary graft dysfunction (PGD) is the most common post-operative complication and a major factor in early mortality and morbidity, affecting ~25% of lung transplant patients. Induced by ischemia reperfusion, PGD represents a severe and acute lung injury that occurs within the first 72 hours after transplantation, and has a significant impact on short- and long-term outcomes, and a significant increase in treatment costs. Any intervention that reduces the risk of PGD will lead to major improvements in short- and long-term transplant outcomes and health care systems.

One of the main strategies to reduce the risk and severity of post-transplant PGD is to improve pre-transplant donor lung preservation methods. In current practice, lung preservation is typically performed by cold flushing the organ with a specialized preservation solution, followed by subsequent hypothermic storage on ice (~4°C). This method continues to be used and applied across different organ systems due to its simplicity and low cost. Using this method for the preservation of donor lungs, the current maximum accepted preservation times have been limited to approximately 6-8h. While the goal of hypothermic storage is to sustain cellular viability during ischemic time through reduced cellular metabolism, lower organ temperature has also been shown to progressively favor mitochondrial dysfunction. Therefore, the ideal temperature for donor organ preservation remains to be defined and should maintain a balance between avoidance of mitochondrial dysfunction and prevention of cellular exhaustion. In addition to that, safe and longer preservation times can lead to multiple advantages such as moving overnight transplants to daytime, more flexibility to transplant logistics, more time for proper donor to recipient matching etc.

Read more

Building on pre-clinical research suggesting that 10°C may be the optimal lung storage temperature, a prospective, multi-center, non-randomized clinical trial was conducted at University Health Network, Medical University of Vienna and Puerta de Hierro Majadahonda University Hospital. Donor lungs meeting criteria for direct transplantation and with cross clamp times between 6:00pm - 4:00am were intentionally delayed to an earliest allowed start time of 6:00am and a maximum preservation time from donor cold flush to recipient anesthesia start time of 12 hours. Lungs were retrieved and transported in the usual fashion using a cooler with ice and transferred to a 10°C temperature-controlled cooler upon arrival to transplant hospital until implantation. The primary outcome of this study was incidence of Primary Graft Dysfunction (PGD) Grade 3 at 72h, with secondary endpoints including: recipient time on the ventilator, ICU Length of Stay (LOS), hospital LOS, 30-day survival and lung function at 1-year. Outcomes were compared to a contemporaneous conventionally transplanted recipient cohort using propensity score matching at a 1:2 ratio. 70 patients were included in the study arm. Post-transplant outcomes were comparable between the two groups for up to 1 year. Thus, intentional prolongation of donor lung preservation at 10°C was shown to be clinically safe and feasible.

In the current study design, the investigators will conduct a multi-centre, non-inferiority, randomized, controlled trial of 300 participants to compare donor lung preservation from the time of explant to implant at ~10°C in X°Port Lung Transport Device (Traferox Technologies Inc.) vs a standard ice cooler. When eligible donor lungs become available for a consented recipient, the lungs will be randomized to undergo a preservation protocol using either 10°C (X°Port Lung Transport Device, Traferox Technologies Inc.) or standard of care. The primary outcome of the study is incidence of ISHLT Primary Graft Dysfunction Grade 3 at 72 hours. Post-transplant outcomes will be followed for one year.

Being tested
Lung transplantation after 10°C donor lung preservation, Lung transplantation after standard ice cooler donor lung preservation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Lung transplantation after 10°C donor lung preservationDevice

    When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to 10°C preservation will be stored, transported and preserved in the X°Port Lung Transport Device (Traferox Technologies Inc.) until implant with a maximum time of 12 hours between the donor and recipient surgeries.

  • Lung transplantation after standard ice cooler donor lung preservationDevice

    When suitable donor lungs become available for a, eligible, consented recipient and meet criteria to go straight to transplantation, the lungs randomized to standard preservation will be will be stored, transported and preserved in an ice cooler (~4°C, standard of care) until implant with a maximum time of 6 hours between the donor and recipient surgeries.

Study groups in NCT05898776
Study groupRoleWhat they receive
10°C lung preservationExperimentalNot described
Receives: Device: Lung transplantation after 10°C donor lung preservation
Standard lung preservationActive comparatorNot described
Receives: Device: Lung transplantation after standard ice cooler donor lung preservation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT)

    PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.

    Measured: 72 hours post-transplant

Secondary outcomes (7)
  1. Incidence of Primary Graft Dysfunction Grade 2-3 as per International Society for Heart and Lung Transplantation

    PGD is graded on a scale of 0 to 3 based on ISHLT guidelines, where PGD Grade 3 indicates severe primary graft dysfunction.

    Measured: 0 (ICU arrival), 24, 48, and 72 hours post-transplant

  2. Time on ventilator

    Measured: Index hospitalization (up to 1 year)

  3. Total ICU and hospital length of stay

    Measured: Index hospitalization (up to 1 year)

  4. Overall survival

    Measured: 30 days, 1 year post-transplant

  5. Occurrence of acute rejection

    Measured: 1 year post-transplant

  6. Six minute walk test

    Measured: 1 year post-transplant

  7. Forced expiratory volume - one second (FEV1 in L)

    Measured: 1 year post-transplant

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2023
  2. Study start9 Jun 2023
  3. Primary completion24 Nov 2025
  4. Study completion22 Nov 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
317 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05898776
Sponsor's protocol ID
22-5909
Status last verified
Mar 2026
First submitted
31 May 2023
Last updated
19 Mar 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Lung transplantation after 10°C donor lung preservation and Lung transplantation after standard ice cooler donor lung preservation in people with Lung Transplant and Organ Preservation, run by University Health Network, Toronto at 17 sites in 8 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 19 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in United States, Canada, Spain, Switzerland, Australia and 3 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of Primary Graft Dysfunction (PGD) Grade 3 as per International Society for Heart and Lung Transplantation (ISHLT) (time frame: 72 hours post-transplant). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in